Stock HOWL WEREWOLF THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Real-time Estimate Cboe BZX
Other stock markets
 12:29:52 2024-06-05 pm EDT 		5-day change 1st Jan Change
3.63 USD -0.27% Intraday chart for Werewolf Therapeutics, Inc. -29.37% -6.87%
Jun. 01 Werewolf Therapeutics to Present Data from Ongoing Phase 1/1B Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors CI
May. 23 Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
AQ
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1B Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
CI
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
AQ
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
AQ
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
CI
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
AQ
Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting
CI
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
AQ
Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics
CI
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
AQ
JMP Securities Starts Werewolf Therapeutics With Market Outperform Rating, $12 Price Target
MT
Werewolf Therapeutics' Q4 Net Loss Narrows
MT
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
AQ
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HOWL Stock
  4. News Werewolf Therapeutics, Inc.